Limits...
Corneal Collagen Cross-Linking in the Treatment of Progressive Keratoconus: A Randomized Controlled Contralateral Eye Study.

Seyedian MA, Aliakbari S, Miraftab M, Hashemi H, Asgari S, Khabazkhoob M - Middle East Afr J Ophthalmol (2015 Jul-Sep)

Bottom Line: P <0.05 was considered as statistically significant.BSCVA improved slightly (a decrease of 0.13 LogMAR) and decreased slightly in the control group (a 0.01 LogMAR increase).The difference between groups was statistically significant (P = 0.014).

View Article: PubMed Central - PubMed

Affiliation: Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran.

ABSTRACT

Background: To assess the short-term efficacy and safety of corneal collagen cross-linking (CXL) in preventing the progression of keratoconus (KCN).

Materials and methods: This randomized controlled clinical trial enrolled 26 patients diagnosed with bilateral progressive KCN and were eligible for CXL. In each patient, one eye was randomly selected for treatment, and the contralateral eye served as the control. The patients underwent CXL with riboflavin drops and ultraviolet radiation in the treated eye. One year follow-up data are presented. Postoperatively, patients were assessed for progression of KCN, visual changes, and other findings. The main outcome measures were maximum simulated keratometry (K-max), best spectacle-corrected visual acuity (BSCVA), and average simulated keratometry. P <0.05 was considered as statistically significant.

Results: In the treated eyes, the mean K-max values decreased by 0.22 D at 1-year postoperatively and increased by 0.41 D in the control group. This difference was statistically significant (P < 0.001). BSCVA improved slightly (a decrease of 0.13 LogMAR) and decreased slightly in the control group (a 0.01 LogMAR increase). The difference between groups was statistically significant (P = 0.014). There was no decrease in visual acuity attributable to complications of CXL in the treated eyes. At 1-year, the keratometry in 3 (12%) treated eyes increased by more than 0.50 D and were considered cases of failed treatment.

Conclusion: Preliminary and 1-year results indicate CXL can halt the progression of KCN in most cases without causing serious complications.

Show MeSH

Related in: MedlinePlus

Comparison of spherical equivalent values in the two groups over time
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4502179&req=5

Figure 4: Comparison of spherical equivalent values in the two groups over time

Mentions: Figure 4 presents the changes in spherical equivalent for both groups. The spherical equivalent improved after treatment compare to before CXL in the treated group and deteriorated in the control group. There was 0.54 ± 1.65 D less myopia in the treated group compared to 0.4 ± 1.46 D more myopia in the control group (P = 0.125).


Corneal Collagen Cross-Linking in the Treatment of Progressive Keratoconus: A Randomized Controlled Contralateral Eye Study.

Seyedian MA, Aliakbari S, Miraftab M, Hashemi H, Asgari S, Khabazkhoob M - Middle East Afr J Ophthalmol (2015 Jul-Sep)

Comparison of spherical equivalent values in the two groups over time
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4502179&req=5

Figure 4: Comparison of spherical equivalent values in the two groups over time
Mentions: Figure 4 presents the changes in spherical equivalent for both groups. The spherical equivalent improved after treatment compare to before CXL in the treated group and deteriorated in the control group. There was 0.54 ± 1.65 D less myopia in the treated group compared to 0.4 ± 1.46 D more myopia in the control group (P = 0.125).

Bottom Line: P <0.05 was considered as statistically significant.BSCVA improved slightly (a decrease of 0.13 LogMAR) and decreased slightly in the control group (a 0.01 LogMAR increase).The difference between groups was statistically significant (P = 0.014).

View Article: PubMed Central - PubMed

Affiliation: Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran.

ABSTRACT

Background: To assess the short-term efficacy and safety of corneal collagen cross-linking (CXL) in preventing the progression of keratoconus (KCN).

Materials and methods: This randomized controlled clinical trial enrolled 26 patients diagnosed with bilateral progressive KCN and were eligible for CXL. In each patient, one eye was randomly selected for treatment, and the contralateral eye served as the control. The patients underwent CXL with riboflavin drops and ultraviolet radiation in the treated eye. One year follow-up data are presented. Postoperatively, patients were assessed for progression of KCN, visual changes, and other findings. The main outcome measures were maximum simulated keratometry (K-max), best spectacle-corrected visual acuity (BSCVA), and average simulated keratometry. P <0.05 was considered as statistically significant.

Results: In the treated eyes, the mean K-max values decreased by 0.22 D at 1-year postoperatively and increased by 0.41 D in the control group. This difference was statistically significant (P < 0.001). BSCVA improved slightly (a decrease of 0.13 LogMAR) and decreased slightly in the control group (a 0.01 LogMAR increase). The difference between groups was statistically significant (P = 0.014). There was no decrease in visual acuity attributable to complications of CXL in the treated eyes. At 1-year, the keratometry in 3 (12%) treated eyes increased by more than 0.50 D and were considered cases of failed treatment.

Conclusion: Preliminary and 1-year results indicate CXL can halt the progression of KCN in most cases without causing serious complications.

Show MeSH
Related in: MedlinePlus